Shon expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment

HIGHLIGHTS

• who: Tarek M. A. Abdel-Fatah from the DepartmentUniversity of, Shenzhen, Guangdong, China have published the Article: SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment, in the Journal: (JOURNAL) of 18/Oct/2018
• what: The authors analysed SHON protein expression in a large cohort of breast tumours by immunohistochemical (IHC) staining using a newly generated anti-SHON monoclonal antibody and determined the relationship of SHON expression with the clinical outcome of chemotherapy-treated patients in another two independent cohorts. The study has clearly demonstrated . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.